AVBP Q2 2025 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$34M

Net Income

-$31M

EPS (Diluted)

$-0.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$270M

Total Liabilities

$20M

Stockholders' Equity

$250M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$34M	-$26M	-30.8%
Net Income	-$31M	-$22M	-43.5%